At SIU Medicine, our researchers perform clinical trials and research studies with the aim of translating findings into new, more effective treatments.
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in subjects who have inadequate response to antipsychotic treatment.
CT-155-R-001: The purpose of this study is to investigate if digital therapeutics (a moblie software application) can help treat certain symptoms of schizophrenia.
To evaluate the efficacy and safety of CT-155 in reducing experiential negative symptoms, compared with a Digital Control, in adult and late adolescent participants diagnosed with schizophrenia.
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).
